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Ischaemic stroke and liver fibrosis 
 
Stroke is the sudden onset of acute neurological injury arising as a result of cerebral haemorrhage or 
ischaemia.  It is common and serious, with 16.9 million incident strokes deduced to have occurred in 
2010 causing 5.9 million deaths worldwide.  It is also a major cause of disability, incurring a 
significant healthcare burden.  Ischaemic stroke is responsible for about 80% of cases in the 
developed world.  Focal ischaemia results from blockage of a blood vessel by a thrombus or 
embolus, preventing blood supply to a region of the brain.(1)  Brain tissue is exquisitely sensitive to 
interruption of blood flow which delivers glucose and oxygen.   
Stroke and other cardiovascular diseases have been associated with various biomarkers and 
parameters of liver disease.  Non-alcoholic liver disease (NAFLD) is the most common cause of liver 
dysfunction, affecting ~20-30% of adults in Western countries.  It spans pathologies ranging from 
simple fatty liver (steatosis; hepatocellular triglyceride content >5%) to necro-inflammatory non-
alcoholic steatohepatitis (NASH), including scarring (fibrosis) and the formation of nodules 
surrounded by fibrotic bands (cirrhosis).  For a diagnosis of NAFLD, secondary causes and excess 
alcohol consumption (≥30g / day for men and ≥20g for women) must be excluded.(2)  NAFLD is 
associated with the conditions that define metabolic syndrome (abdominal obesity, high blood 
pressure, high fasting glucose, high triglycerides and low HDL levels) and hence patients, particularly 
those with NASH, may be at increased risk of cardiovascular disease, due to shared risk factors.(3)  
NAFLD and especially NASH may exacerbate hepatic and systemic insulin resistance, leading to 
dyslipidaemia, atherogenesis and increased cardiovascular disease risk.  Remarkably, in NAFLD, 
cardiovascular disease is more commonly responsible for death than is liver disease.(2;4;5)  The 
relationship between ischaemic stroke and liver stiffness, as an indicator of hepatic fibrosis, is 
examined in the paper published by Kim and colleagues in this issue of Atherosclerosis.(6)  These 
authors investigated 295 patients admitted with acute ischaemic stroke compared to 1,942 control 
subjects having a medical check-up, in Seoul, Korea.  The most common causes of stroke were 
cardioembolism (39.5%), more than two causes (26.2%) and large artery atherothrombosis (12.9%).  
Patients with chronic viral hepatitis or alcohol consumption of >40g/day for >5 years were excluded.  
Liver stiffness was assessed non-invasively by ultrasound investigation using transient elastography; 
values <5.6kPa were taken as within the normal range.  Liver steatosis was also assessed during the 
same examination via attenuation of the ultrasound signal as the controlled attenuation parameter 
(CAP); values >250dB/min were taken as an indicator of fatty liver.   
While normal liver stiffness was observed in a greater proportion of the control group than the 
stroke group (90.6% vs. 69.2%, p<0.001) and a greater proportion of the stroke group had significant 
liver fibrosis (>8 kPa) than the control group (9.2% vs. 1.8%, p<0.001), the proportion with fatty liver 
(defined by CAP) did not differ between the groups (42.4% vs. 41.0%, p=0.665).  Similarly, the mean 
liver stiffness of the stroke group was greater than that of the control group (5.6 vs. 4.1kPa, 
p<0.001), whereas the mean CAP value did not differ between the groups (242.1 vs. 243.5dB/m, 
p=0.646).   After stratifying according to either being overweight (BMI ≤ or >25), having fatty liver 
(CAP ≤ or >250) and the presence or absence of metabolic syndrome, mean liver stiffness remained 
significantly greater in all stroke vs. control subgroups.   
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The severity of fibrosis was compared between stroke and control groups using multiple logistic 
regression analysis.  The odds ratio (OR) for ischaemic stroke was 1.268 (95% confidence intervals 
1.183-1.358, p<0.001) per 1 kPa increase in liver stiffness.  OR for ischaemic stroke in the context of 
mild fibrosis was 4.308 (2.680-6.925, p<0.001) and of significant fibrosis was 12.033 (5.180-27.948, 
p<0.001), versus no fibrosis.  Consistent results were obtained after propensity-score matched 
analysis of the subset of 189 cases and 189 controls: the OR for ischaemic stroke was 1.804 (1.461-
2.230, p<0.001) per 1 kPa increase; OR for ischaemic stroke in the context of mild fibrosis (5.6-8.0 
kPa) was 4.577 (2.354-8.900, p<0.001) and of significant fibrosis was 13.184 (3.127-55.645, p<0.001), 
versus no fibrosis.   
The study population was also stratified using serum alanine aminotransferase (ALT) levels, as a 
marker of hepatocellular damage, into patients with normal ALT levels and those with levels above 
the upper normal limit of 0.67µkat/L (>40 IU/L).  In patients with normal ALT levels, OR for ischaemic 
stroke was 1.708 (1.472-1.982, p<0.001) per 1 kPa increase in liver stiffness.  OR for ischaemic stroke 
in the context of mild fibrosis was 4.661 (2.609-8.325, p<0.001) and of significant fibrosis was 6.805 
(2.321-19.950, p<0.001), versus no fibrosis.  In patients with ALT levels above the normal range, risk 
of ischaemic stroke was again associated with liver stiffness when analysed as a categorical variable, 
but not when analysed as a continuous variable.  This may reflect previous observations that in 
patients with chronic hepatitis B, elevated ALT may be associated with over-estimation of liver 
stiffness by TE.(7)   
Overall, this study(6) is the first to show an association between the degree of liver fibrosis and risk 
of ischaemic stroke.  This chimes with the previous observation that only NAFLD patients with 
fibrosis stage 3-4 (irrespective of the NAFLD activity score) had increased cardiovascular mortality, 
compared to a reference population.(5)  Three previous studies (total subjects 2,241) have assessed 
stroke or transient ischaemic attack (excluding cerebral haemorrhage) in a prospective fashion, in 
subjects diagnosed with NAFLD by ultrasonography.  Meta-analysis found stroke risk was higher in 
the group with NAFLD vs. the group without NAFLD (relative risk 2.09; 95% CI 1.46-2.98, p<0.001).(8)   
Genetic risk factors have been proposed to predispose to NAFLD via four pathways, influencing 
glucose metabolism and insulin sensitivity, steatosis, steatohepatitis and the development of 
fibrosis.(9) Kim and colleagues did not investigate genetic risk factors for either stroke or NAFLD (and 
large studies would be required for this); however, there is an apparent lack of overlap between 
genome-wide significant associations for ischaemic stroke and NAFLD.(6;9-12)  Several putative 
modifier variants have been reported for liver steatosis or histological evidence of NAFLD and a few 
genome-wide significant associations have been replicated.  The s738409 variant in PNPLA3 
predicting isoleucine to methionine substitution (Ile148Met) has been robustly associated with 
serum biochemical markers of NAFLD and hepatic steatosis.  The Ile148Met protein has impaired 
triglyceride hydrolysis activity, coating hepatic lipid droplets and blocking access of other lipolytic 
enzymes, leading to accumulation of hepatic triglyceride.(13)  Carriers of Ile148Met also secreted 
less of the large, triglyceride – rich very low density lipoprotein (VLDL1) particles from the liver than 
did wild type Ile148 homozygotes, for any given liver fat content.(14).  For ischaemic stroke, 
genome-wide significant associations with specific stroke subtypes suggest clues to mechanism: 
PITX2 and ZFHX3 were associated with cardioembolic stroke, consistent with their original 
association with atrial fibrillation.(11) The HDAC9 and 9p21 associations were specific to large vessel 
stroke.  ABO (encoding ABO blood group) was associated with all ischaemic stroke and large vessel 
and cardioembolic stroke.(10) The ABO single nucleotide polymorphism (SNP), rs505922, was 
previously associated with levels of the clotting factors, von Willebrand factor and Factor VIII, 
consistent with a thrombotic mechanism. However, SNPs in the ABO locus have widespread 
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pleiotropic effects upon a range of cardiometabolic traits. For example, the lead ischaemic stroke 
SNP, rs532436, has been associated with red blood cell traits, lower haematocrit and haemoglobin, 
so in the case of a partly blocked artery, lower oxygen transport capacity of blood could be a 
potential contributing mechanism.(10;15;16)  In line with this, a study of ~50,000 subjects with 
stroke and 150,000 controls associated ischaemic stroke with iron deficiency anaemia.(17) 
While liver biopsy is the gold standard for histological evaluation of NAFLD, allowing assessment of 
liver architecture, it is invasive and has potential for sampling error. Transient elastography is a 
widely used, non-invasive reference technique; 10 repeated measurements were made and 
measurements with interquartile range > 30% of median were rejected.(6)  However, it may be 
unreliable for patients with high BMI and/or high thoracic fold thickness and the presence of 
steatosis may cause false positive results.(2;18)  The CAP value can detect steatosis, is non-invasive 
and can be performed alongside transient elastography; however its discrimination of histological 
grades of steatosis is limited and more data are required to define its use.(19)  
The findings of Kim and colleagues (6) merit further validation and replication in large, highly -  
phenotyped prospective observational cohorts with hepatic, cardiometabolic and stroke - related 
data, genotype and other “–omics” measurements.  The potential overlap between genetic risk 
factors, signalling pathways affected by genetic variants and their tissue expression patterns, along 
with causality, remain fertile ground for exploration.  These observations on Korean patients should 
be investigated across cohorts of different ethnicities.   If confirmed, they suggest a number of 
interesting questions and avenues.  Firstly, is the association of liver stiffness with ischaemic stroke 
due only to shared risk factors?  Secondly, the role of simple steatosis vs. NASH remains to be 
resolved in stroke risk: does hepatic inflammation add to stroke risk?  Thirdly, would improvement in 
fatty liver disease reduce the risk of ischaemic stroke?  Exploration of the relationship between 
ischaemic stroke risk and liver fibrosis has potential for utility, as well as providing insight into the 
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